Certified by Founder Lodge
Mediar Therapeutics
United States - Cambridge, MA
START UP
1 Disclosed Funding Rounds $105,000,000
0 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Mediar Therapeutics is a biotechnology company pioneering a new approach to fibrosis treatment that halts the disease at a different source – the fibrotic mediators that drive disease progres
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| March, 15 ,2023 | Unknown | $105,000,000 | |
| January, 09 ,2026 | Series B | $76,000,000.00 |
Eli Lilly and Company
Pfizer
Sofinnova Partners
Mission BioCapital
Mass General Brigham Ventures
Bristol Myers Squibb
Pureos Bioventures
Gimv
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
PaleBlueDot AI | $150,000,000 | (Jan 30, 2026)
WealthAi | $1,000,000 | (Jan 30, 2026)
Datalinx AI | $4,200,000 | (Jan 30, 2026)
Ressio Software | Undisclosed Amount | (Jan 30, 2026)
Checkbox | $23,000,000 | (Jan 30, 2026)
